Q32 Bio is a clinical-stage biotechnology enterprise specializing in the development of targeted biological therapeutics designed to rebalance immune homeostasis. The name reflects the company's core scientific mission centered around modulating complex immunological pathways, such as interleukin-7 receptor and complement system cascades, to provide meaningful therapeutic interventions for patients suffering from debilitating autoimmune, inflammatory, and rare systemic diseases.